Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Salt – page 17

330 clinical trials in Salt, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Salt at a glance
330
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

330 trials in Salt

Open in trial search

COVID-19

Not recruiting

Study on the Safety and Immune Response of BIMERVAX as a COVID-19 Booster in Adolescents Aged 12 to 17 Years

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · Healthy volunteers
  • Substances:SARS-COV-2 VIRUS, VARIANTS B.1.351-B.1.1.7, SPIKE PROTEIN, RECEPTOR BINDING DOMAIN FUSION HETERODIMER
  • Sponsor:Hipra Scientific S.L.

Breast cancer+2

Not recruiting

Study on Denosumab to Prevent Breast Cancer in Women with BRCA1 Mutation

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · Healthy volunteers
  • Substances:Denosumab
  • Sponsor:ANZ Breast Cancer Trials Group Limited

Herpes zoster

Not recruiting

Study on Long-Term Effects and Safety of Herpes Zoster Vaccine with Recombinant Varicella Zoster Virus Glycoprotein E in Older Adults

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Sponsor:GlaxoSmithKline Biologicals

COVID-19+1

Not recruiting

Study on the Safety of BIMERVAX and Fluad Tetra for COVID-19 and Influenza in Adults Over 65 Who Are Fully Vaccinated Against COVID-19

Registered drug
Countries:SpainSpain
  • Participants:65+ years · Healthy volunteers
  • Substances:A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)
  • Sponsor:Hipra Scientific S.L.

Chronic myeloid leukaemia

Not recruiting

Study for Adults with Chronic Myeloid Leukemia Using Asciminib Alone or with Nilotinib

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets

Triple negative breast cancer

Not recruiting

Study of Pembrolizumab, Carboplatin, and Paclitaxel for Patients with Stage I Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Medica Scientia Innovation Research S.L.

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing Acasunlimab and Pembrolizumab with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acasunlimab
  • Sponsor:Genmab A/S

Relapsing-remitting multiple sclerosis

Not recruiting

Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Amgen Inc.

Chronic lymphocytic leukaemia+1

Not recruiting

Study of Lisaftoclax and Acalabrutinib for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Ascentage Pharma Group Inc.

Hormone-refractory prostate cancer+2

Not recruiting

Study of Fuzuloparib, Abiraterone Acetate, and Prednisone for First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Jiangsu Hengrui Pharmaceuticals Co. Ltd.

Cushing's syndrome

Not recruiting

Study on the Long-Term Safety of Relacorilant for Patients with Cushing Syndrome

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Corcept Therapeutics Inc.

Pancreatic carcinoma

Not recruiting

Study on Quemliclustat and Chemotherapy for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Arcus Biosciences Inc.

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in Salt

What the registry says about research in the country

01 Multiple Sclerosis Research

Extensive research focusing on relapsing-remitting multiple sclerosis and its treatment approaches, including comparative studies of novel therapies and established medications.

  • Treatment Comparisons
  • Long-term Safety Studies
  • Disease Progression Management

Multiple innovative therapies are being evaluated to improve patient outcomes and reduce disease progression.

02 Progressive MS Studies

Dedicated research into Primary Progressive Multiple Sclerosis (PPMS), exploring new therapeutic options through targeted treatment approaches.

  • Disability Progression
  • Novel Treatment Mechanisms
  • Long-term Effectiveness

Studies focus on developing treatments to delay disability progression in PPMS patients.

03 Specialized Conditions

Research addressing specific medical conditions including severe primary hand hyperhidrosis and pregnancy-related conditions such as nausea and vomiting.

  • Topical Treatments
  • Pregnancy-related Conditions
  • Quality of Life Improvements

Clinical investigations aim to enhance treatment options and patient comfort across various conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.